A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and more patient data was extremely unlikely to change the trial’s outcome. Read about it here.
top of page
Recent Posts
See AllThe Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
320
Calls for strengthening health systems in preparation for the next pandemic have intensified in the wake of COVID-19, with estimates ranging from $15 billion to $50 billion needed annually to scale up
530
The monitoring and evaluation framework of the TB Action Plan for the WHO European Region 2023–2030 includes four new indicators reflecting consistent meaningful engagement of the communities and civi
540
bottom of page